Johnson & Johnson closing in on COVID-19 vaccine supply deal in Europe

The European Commission (EC) has finished exploratory talks with Johnson & Johnson (JNJ -0.8%) about a potential contract to supply up to 200M doses of its COVID-19 vaccine, if approved, to member states. The agreement, if consummated, may include an option to buy up to 200M additional doses.

The EU has allocated €2B ($2.3B) to procure vaccines from up to six producers.

The EC concluded exploratory discussions with representatives of Sanofi (SNY -0.7%) and adjuvant supplier GlaxoSmithKline (GSK -1.1%) in late July.


Read More   Kotak Mahindra Bank’s preference share issue not as per regulations: RBI

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.